Efficacy of local injection therapy with hyaluronic acid of different molecular weight in patients with knee osteoarthritis

Intra-articular administration of hyaluronic acid (HA) is one of the methods of conservative treatment of knee osteoarthritis (OA). However, the data of its efficacy in the modern literature are contradictory.

Objective: to assess the efficacy of intra-articular administration of HA preparations with different molecular weight in the treatment of patients with knee OA and to study the factors that can influence the effectiveness of such therapy.

Subjects and methods. HA preparations were administered to 60 patients with idiopathic and posttraumatic knee OA. The ratio of women to men was 3:1. The average age was 59.5±13.7 years and body mass index – 30.3±5.8 kg/m². The presence of enthesitis was evaluated prior to treatment by the characteristic clinical picture. The x-ray stage of OA was determined in accordance with the classification of Kellgren–Lawrence. Distribution of of knee joint lesions, relationship of femur and tibia anatomical axes, presence of varus and valgus deformities were also evaluated. The patients were divided into three groups: 18 patients received low-molecular (LM), 19 – medium-molecular (MM) and 23 – high-molecular (HM) HA. To assess the efficacy of the treatment the severity of pain on a visual analog scale (VAS) and the total score of the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire before, 1, 3 and 6 months after treatment were evaluated.

Results and discussion. Enthesitis was detected in 17 (28,3%) patients. Stage I of knee OA was diagnosed in 10 (16.6%), II – in 36 (60%) and III – in 14 (23.3%) patients. Varus deformity was detected in 43 (71.7%) patients, neutral axis of the lower limb - in 14 (23.3%), valgus deformity – in 3 (5%). The most significant decrease in the severity of pain was noted in patients with stage I of knee OA: from 54±17.1 to 10.0±10.0 mm. At stage II, the pain decreased from 59.4±12.6 to 45.5±20.3 mm, and at stage III – from 66.4±13.5 to 60.7±23.3 mm. By the 6th month, the severity of pain in patients with enthesitis was higher, and the values of KOOS total score were worse than in patients without it. At stages II and III of knee OA, the ratio of positive to unsatisfactory results for MM, LM and HM HA was as follows: 2:1, 3:1 and 3.6:1. In the group of patients with excellent results, the value of varus deformation averaged 8.5±1.5°, in patients with a good result – 9.8±2.8°, with a satisfactory result – 11.3±4.5°, and with an unsatisfactory – 11.5±3.2°.

Conclusion. Intra-articular injection of HA is very effective at stage I of knee OA. The expression and duration of this effect are reducedwith decrease of cartilage thickness and increase of knee joint varus deformation (i.e., at the II and III stages of knee OA). The presence of varus deformation does not affect HA efficacy. Three factors are important: the appearance of varus deformation of the lower limb with initially neutral axis; the increase of varus deformation; the value of varus deformation >10°.

1. Brandt KD, Doherty M, Stefan Lohmander LS. Osteoarthritis. Oxford: Oxford Medical Publications; 1998. 598 p.

2. Freitag J, Bates D, Boyd R, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy – a review. BMC Musculoskelet Disord. 2016 May 26;17:230. doi: 10.1186/s12891-016-1085-9

3. Pereira D, Peleteiro B, Araujo J, et al. The effect of osteoarthritis definition on prevalence and incidence osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage. 2011;19(11):1270-85. doi: 10.1016/j.joca.2011.08.009

4. Solov'eva IV, Strebkova EA, Alekseeva LI, Mkrtumyan AM. The effect of weight loss on the manifestations of osteoarthritis of the knee. Ozhirenie i Metabolizm. 2014;(4):41-7 (In Russ.). doi: 10.14341/OMET2014441-47

5. Badokin VV. Knee osteoarthrosis: Clinical presentation, diagnosis, treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(3):70-5 (In Russ.). doi: 10.14412/1996-7012-2013-277

6. Alekseeva LI, Zaitseva EM. Perspective lines of therapy for osteoarthrosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):247-50 (In Russ.). doi: 10.14412/1995-4484-2014-247-250

7. Karateev AE, Alekseeva LI, Filatova EG, et al. Obezbolivayushchie preparaty v terapevticheskoi praktike [Painkillers in therapeutic practice]. Moscow: IMA-PRESS; 2013. P. 136 (In Russ.).

8. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.). ISBN 978-5-9704-4261-6.

9. Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014 Jun;43(6):701-12. doi: 10.1016/j.semarthrit.2013.11.012. Epub 2013 Dec 4.

10. Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.). doi: 10.14412/1996-7012-2015-1-4-23

11. Khabarov VN, Boikov PYa, Kolosov VA, Ivanov PL; Khabarov VN, editor. Gialuronan v artrologii. Kompleksy gialuronovoi kisloty s nizkomolekulyarnymi bioregulyatorami – novaya stranitsa v lechenii sustavnykh patologii[Hyaluronan in arthrology. Hyaluronic acid complexes with low molecular weight bioregulators – a new page in the treatment of articular pathologies]. Moscow: Advansed solyushnz; 2014. 208 p. (In Russ.). ISBN 978-5-906722-14-0

12. Knudson W, Loeser RF. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cel Mol Life Sci. 2002;59:36-44. doi: 10.1007/s00018-002-8403-0

13. Smith MM, Cake MA, Ghosh P, et al. Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford). 2008;47(8):1172-8. doi: 10.1093/rheumatology/ken219

14. Bagga H, Burkhardt D, Sambrook P, March L. Long-term effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee.J Rheumatol. 2006 May;33(5):946-50.

15. Waller KA, Zhang LX, Fleming BC, Jay GD. Preventing frictioninduced chondrocyte apoptosis: comparison of human synovial fluid and hylan G-F 20. J Rheumatol. 2012 Jul;39(7):1473-80. doi: 10.3899/jrheum.111427. Epub 2012 Jun 1.

16. Homandberg GA, Ummadi V, Kang H. The role of insulin-like growth factor-I in hyaluronan mediated repair of cultured cartilage explants. Inflamm Res. 2004 Aug;53(8):396-404. Epub 2004 Aug 10.

17. Campo GM, Avenoso A, Nastasi G, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011 Sep;1812(9):1170-81. doi: 10.1016/j.bbadis.2011.06.006. Epub 2011 Jun 21.

18. Petukhov AI, Kornilov NN, Kulyaba TA. Injectable hyaluronic acid drugs for the treatment of knee osteoarthritis in the context of evidence-based medicine. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice.2018;56(2):239-48 (In Russ.). doi: 10.14412/1995-4484-2018-239-248

19. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Apr;43(5):593-9. doi: 10.1016/j.semarthrit.2013.10.002. Epub 2013 Oct 14.

20. Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012 Aug 1;26(4):257-68. doi: 10.2165/11632580-000000000-00000

21. Bruyere O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord. 2008 Dec 16;9:165. doi: 10.1186/1471-2474-9-165

22. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res. 2007 Feb;455:113-22. doi: 10.1097/BLO.0b013e31802f5421

23. Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intraarticular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis Cartilage. 2011 Jun;19(6):611-9. doi: 10.1016/j.joca.2010.09.014. Epub 2011 Apr 9.

24. Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review of the Evidence. J Bone Joint Surg Am. 2015 Dec 16;97(24):2047-60. doi: 10.2106/JBJS.N.00743

25. Pai SK, Allgar V, Giannoudis PV. Are intra-articular injections of Hylan G-F 20 efficacious in painful osteoarthritis of the knee? A systematic review & meta-analysis. Int J Clin Pract. 2014 Aug;68(8):1041-7. doi: 10.1111/ijcp.12430. Epub 2014 May 5.

26. Altman RD, Schemitsch E, Bedi A. Assessment of clinical practice guideline methodology for the treatment of knee osteoarthritis with intra-articular hyaluronic acid. Semin Arthritis Rheum. 2015;45(2):132-9. doi: 10.1016/j.semarthrit.2015.04.013

27. Vannabouathong C, Bhandari M, Bedi A, et al. Nonoperative treatments for knee osteoarthritis: An evaluation of treatment characteristics and the intra-articular placebo effect. A systematic review. JBJS Rev. 2018;6(7):e5. doi: 10.2106/JBJS.RVW.17.00167

28. Bowman EN, Hallock JD, Throckmorton TW, Azar FM. Hyaluronic acid injections for osteoarthritis of the knee: predictors of successful treatment.Int Orthopaed. 2018;42(4):733-40. doi: 10.1007/s00264-017-3731-8